Brief: Agenus To Receive $25 Mln Milestone Payment From Bristol Myers Squibb For TIGIT-CD96 Bispecific Program
11/12/2023 12:38
Dec 11 (Reuters) - Agenus Inc AGEN.O :
* AGENUS TO RECEIVE $25 MILLION MILESTONE PAYMENT FROM
BRISTOL
MYERS SQUIBB FOR TIGIT-CD96 BISPECIFIC PROGRAM
* AGENUS INC - WILL RECEIVE $25 MILLION CASH PAYMENT FROM
BRISTOL
MYERS SQUIBB WITH DOSING OF FIRST PATIENT IN PHASE 2 DOSE
EXPANSION PORTION
Source text for Eikon: ID:nBw9pxN0Xa
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income